 | 1999 - 220 lapas
...(including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general...orally, nasally, rectally, or vaginally containing PD&C Yellow No. 6 shall specifically declare the presence of PD&C Yellow No. 6 by listing the color... | |
 | 1994 - 196 lapas
...(including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general...human use administered orally, nasally, rectally, or vaglnally containing FD&C Yellow No. 6 shall specifically declare the presence of FD&C Yellow No. 6... | |
 | 1984 - 202 lapas
...(including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general...aspirin hypersensitivity." This warning statement shall Chapter I Food and Drug Administration appear in the "Precautions" section of the labeling. (Secs.... | |
 | 1987 - 454 lapas
...to the requirements of § 70.25 of this chapter. (2) The label of over-the-counter and prescription drug products intended for human use administered...Yellow No. 6 shall specifically declare the presence of FD&C Yellow No. 6 by listing the color additive using the names FD&C Yellow No. 6 and Sunset Yellow.... | |
 | 1989 - 240 lapas
...(including bronchial asthma) in certain susceptible persons. Although the overall Incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in pa§201.22 tients who also have aspirin hypersensitivity." This warning statement shall appear in the... | |
 | 1992 - 192 lapas
...FD&C Yellow No. 6 in certain drugs for human use. (a) The label for over-the-counter and prescription drug products intended for human use administered...rectally, or vaginally containing FD&C Yellow No. 5 shall specifically declare the presence of FD&C Yellow No. 5 as a color additive using the names... | |
 | 1997 - 468 lapas
...shall conform to the requirements of §70.25 of this chapter. (2) The label of OTC and prescription drug products intended for human use administered orally, nasally, rectally, or vaginally, or for use in the area of the eye, containing FD&C Yellow No. 5 shall specifically declare the presence... | |
 | 2000 - 232 lapas
...FD&C Yellow No. 6 in certain drugs for human use. (a) The label for over-the-counter and prescription drug products intended for human use administered orally, nasally, rectally, or vaginally, or for use in the area of the eye, containing FD&C Yellow No. 5 as a color additive using the names... | |
 | 1997 - 200 lapas
...FD&C Yellow No. в in certain drugs for human use. (a) The label for over-the-counter and prescription drug products intended for human use administered orally, na-sally, rectally, or vaginally, or for use in the area of the eye, containing FD&C Yellow No. 5 as a color additive using the names... | |
 | 1981 - 402 lapas
...(including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Ye1low No. 5 (tartrazine) sensitivity in the general population...appear in the "Precautions" section of the labeling. (d) Certification. All batches of FD&C Yellow No. 5 shall be certified in accordance with regulations... | |
| |
USP) 2.5, 5, and 10 mg contain FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible individuals. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the... 
